Document Detail


Overexpression of aldo-keto reductase 1C3 (AKR1C3) in LNCaP cells diverts androgen metabolism towards testosterone resulting in resistance to the 5α-reductase inhibitor finasteride.
MedLine Citation:
PMID:  22265960     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Type 5 17β-hydroxysteroid dehydrogenase (AKR1C3) is the major enzyme in the prostate that reduces 4-androstene-3,17-dione (Δ(4)-Adione) to the androgen receptor (AR) ligand testosterone. AKR1C3 is upregulated in prostate cancer (PCa) and castrate resistant prostate cancer (CRPC) that develops after androgen deprivation therapy. PCa and CRPC often depend on intratumoral androgen biosynthesis and upregulation of AKR1C3 could contribute to intracellular synthesis of AR ligands and stimulation of proliferation through AR signaling. To test this hypothesis, we developed an LNCaP prostate cancer cell line overexpressing AKR1C3 (LNCaP-AKR1C3) and compared its metabolic and proliferative responses to Δ(4)-Adione treatment with that of the parental, AKR1C3 negative LNCaP cells. In LNCaP and LNCaP-AKR1C3 cells, metabolism proceeded via 5α-reduction to form 5α-androstane-3,17-dione and then (epi)androsterone-3-glucuronide. LNCaP-AKR1C3 cells made significantly higher amounts of testosterone-17β-glucuronide. When 5α-reductase was inhibited by finasteride, the production of testosterone-17β-glucuronide was further elevated in LNCaP-AKR1C3 cells. When AKR1C3 activity was inhibited with indomethacin the production of testosterone-17β-glucuronide was significantly decreased. Δ(4)-Adione treatment stimulated cell proliferation in both cell lines. Finasteride inhibited LNCaP cell proliferation, consistent with 5α-androstane-3,17-dione acting as the major metabolite that stimulates growth by binding to the mutated AR. However, LNCaP-AKR1C3 cells were resistant to the growth inhibitory properties of finasteride, consistent with the diversion of Δ(4)-Adione metabolism from 5α-reduced androgens to increased formation of testosterone. Indomethacin did not result in differences in Δ(4)-Adione induced proliferation since this treatment led to the same metabolic profile in LNCaP and LNCaP-AKR1C3 cells. We conclude that AKR1C3 overexpression diverts androgen metabolism to testosterone that results in proliferation in androgen sensitive prostate cancer. This effect is seen despite high levels of uridine glucuronosyl transferases suggesting that AKR1C3 activity can surmount the effects of this elimination pathway. Treatment options in prostate cancer that target 5α-reductase where AKR1C3 co-exists may be less effective due to the diversion of Δ(4)-Adione to testosterone.
Authors:
Michael C Byrns; Rebekka Mindnich; Ling Duan; Trevor M Penning
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't     Date:  2012-01-12
Journal Detail:
Title:  The Journal of steroid biochemistry and molecular biology     Volume:  130     ISSN:  1879-1220     ISO Abbreviation:  J. Steroid Biochem. Mol. Biol.     Publication Date:  2012 May 
Date Detail:
Created Date:  2012-04-02     Completed Date:  2012-06-22     Revised Date:  2014-09-15    
Medline Journal Info:
Nlm Unique ID:  9015483     Medline TA:  J Steroid Biochem Mol Biol     Country:  England    
Other Details:
Languages:  eng     Pagination:  7-15     Citation Subset:  IM    
Copyright Information:
Copyright © 2011 Elsevier Ltd. All rights reserved.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
3-Hydroxysteroid Dehydrogenases / genetics,  metabolism*
5-alpha Reductase Inhibitors / pharmacology*
Androgens / metabolism*
Cell Line, Tumor
Cell Proliferation
Drug Resistance, Neoplasm
Finasteride / pharmacology*
Humans
Hydroxyprostaglandin Dehydrogenases / genetics,  metabolism*
Male
Prostatic Neoplasms / enzymology,  metabolism
Testosterone / metabolism*
Grant Support
ID/Acronym/Agency:
P30 ES013508/ES/NIEHS NIH HHS; P30 ES013508-06/ES/NIEHS NIH HHS; P30-ES013508/ES/NIEHS NIH HHS; R01 CA090744/CA/NCI NIH HHS; R01 CA090744-09/CA/NCI NIH HHS; R01-CA90744/CA/NCI NIH HHS; T32 DK007314/DK/NIDDK NIH HHS; T32 DK007314-25/DK/NIDDK NIH HHS; T32-DK007314-25/DK/NIDDK NIH HHS; T32-HD007305-22/HD/NICHD NIH HHS
Chemical
Reg. No./Substance:
0/5-alpha Reductase Inhibitors; 0/Androgens; 3XMK78S47O/Testosterone; 57GNO57U7G/Finasteride; EC 1.1.-/3-Hydroxysteroid Dehydrogenases; EC 1.1.1.-/AKR1C3 protein, human; EC 1.1.1.-/Hydroxyprostaglandin Dehydrogenases
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Regulation of SVEP1 gene expression by 17?-estradiol and TNF? in pre-osteoblastic and mammary adenoc...
Next Document:  Special considerations in virtual surgical planning for secondary accurate maxillary reconstruction ...